ProPhase Labs stock: Q3 filing delayed for auditor review
Published on 11/19/2026 at 03:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFiling delay keeps results pending
- ProPhase Labs did not file its quarterly report for the period ended September 30, 2026 on time.
- The company develops whole-genome sequencing, diagnostic and consumer health products.
ProPhase Labs said on November 16 that it could not file its quarterly report for the period ended September 30 on time because its independent accounting firm needed additional time to complete review procedures. The company expects to submit the Form 10-Q within the five-calendar-day extension allowed under the filing rules, according to the SEC filing reproduced by StockTitan.
Auditor review delays quarterly filing
The notification says ProPhase is working with its auditors to finalize the financial statements and related disclosures. It also states that the company does not anticipate a significant change in operating results compared with the year-earlier period.
The filing delay leaves investors waiting for the company’s latest quarterly figures, including revenue, cash use and progress in its restructuring and collection efforts. The eventual report should provide the next detailed update on those areas.
Biotech and consumer health portfolio
ProPhase Labs is a United States healthcare company focused on whole-genome sequencing, diagnostic development and consumer products. Its portfolio includes the BE-Smart test for early esophageal-cancer detection, genomics offerings and direct-to-consumer dietary supplements. The company combines laboratory-related activities with health and wellness products.
ProPhase Labs at a glance
- Company: ProPhase Labs, Inc.
- Ticker: PRPH
- Industry: Diagnostics and Research
- Sector: Healthcare
- Headquarters: Uniondale, New York
ProPhase Labs operates in the broader U.S. healthcare market alongside the S&P 500, where healthcare and biotechnology companies remain part of the wider market environment.
More news and analyses on ProPhase Labs stock are available here.
